JP2013534256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534256A5 JP2013534256A5 JP2013525003A JP2013525003A JP2013534256A5 JP 2013534256 A5 JP2013534256 A5 JP 2013534256A5 JP 2013525003 A JP2013525003 A JP 2013525003A JP 2013525003 A JP2013525003 A JP 2013525003A JP 2013534256 A5 JP2013534256 A5 JP 2013534256A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- compound according
- acceptable salt
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 11
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 5
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 5
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 claims 5
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 229960002563 disulfiram Drugs 0.000 claims 5
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 claims 5
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims 5
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 claims 5
- 229950001981 nimetazepam Drugs 0.000 claims 5
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims 5
- 229960003688 tropisetron Drugs 0.000 claims 5
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 2
- 230000003942 amyloidogenic effect Effects 0.000 claims 2
- 230000007450 amyloidogenic pathway Effects 0.000 claims 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 2
- 208000015756 familial Alzheimer disease Diseases 0.000 claims 2
- 210000005171 mammalian brain Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000007505 plaque formation Effects 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40190710P | 2010-08-19 | 2010-08-19 | |
| US61/401,907 | 2010-08-19 | ||
| PCT/US2011/048472 WO2012024616A1 (en) | 2010-08-19 | 2011-08-19 | Methods of treating miild cognitive impairment (mci) and related discorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016160482A Division JP2016193944A (ja) | 2010-08-19 | 2016-08-18 | 軽度の認知障害(mci)および関連障害の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534256A JP2013534256A (ja) | 2013-09-02 |
| JP2013534256A5 true JP2013534256A5 (https=) | 2014-10-09 |
| JP6250394B2 JP6250394B2 (ja) | 2017-12-20 |
Family
ID=45605447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013525003A Active JP6250394B2 (ja) | 2010-08-19 | 2011-08-19 | 軽度の認知障害(mci)および関連障害の処置方法 |
| JP2016160482A Pending JP2016193944A (ja) | 2010-08-19 | 2016-08-18 | 軽度の認知障害(mci)および関連障害の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016160482A Pending JP2016193944A (ja) | 2010-08-19 | 2016-08-18 | 軽度の認知障害(mci)および関連障害の処置方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10449177B2 (https=) |
| EP (1) | EP2605655B1 (https=) |
| JP (2) | JP6250394B2 (https=) |
| AU (1) | AU2011291506B2 (https=) |
| BR (1) | BR112013003847A8 (https=) |
| CA (1) | CA2808630A1 (https=) |
| DK (1) | DK2605655T3 (https=) |
| ES (1) | ES2705027T3 (https=) |
| MX (1) | MX353096B (https=) |
| WO (1) | WO2012024616A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2705027T3 (es) | 2010-08-19 | 2019-03-21 | Buck Institute For Age Res | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados |
| BR112015002309A2 (pt) | 2012-08-07 | 2017-07-04 | Buck Inst Res Aging | formulação de múltiplos componentes para aprimorar a função neurológica |
| CA2899938C (en) | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| US10369108B2 (en) | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| IL286427B2 (en) | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| KR102645633B1 (ko) | 2014-03-21 | 2024-03-11 | 알제온, 인크. | 신경학적 장애를 치료하는 방법 |
| CA2976258C (en) | 2015-02-18 | 2024-02-20 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| AU2016264228B2 (en) * | 2015-05-18 | 2019-06-13 | Synaptec Development Llc | Galantamine clearance of amyloidß |
| EP4275750B1 (en) * | 2015-09-10 | 2026-05-06 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| CA3007641C (en) | 2015-12-09 | 2023-10-17 | Brandeis University | Dbh inhibitors for treating or preventing memory loss |
| US20180250249A1 (en) * | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
| EP3455223B1 (en) | 2016-05-12 | 2023-11-08 | Buck Institute for Research on Aging | Compounds to promote normal processing of app |
| US20210230221A1 (en) | 2017-01-03 | 2021-07-29 | Bioatla, Llc | Protein therapeutics for treatment of senescent cells |
| US11026963B2 (en) | 2018-07-11 | 2021-06-08 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
| CN110232679A (zh) * | 2019-05-24 | 2019-09-13 | 潘丹 | 一种阿尔茨海默症遗传生物标志物确定方法及系统 |
| US12521362B2 (en) | 2019-07-25 | 2026-01-13 | Tokyo University Of Science Foundation | Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
| ES2217250T3 (es) | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
| ES2236682T5 (es) | 1991-01-21 | 2011-03-31 | Elan Pharmaceuticals, Inc. | Ensayo y modelo para la enfermedad de alzheimer. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5206264A (en) | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| AU671093B2 (en) | 1992-01-07 | 1996-08-15 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| WO2000003819A1 (en) | 1998-07-17 | 2000-01-27 | The Penn State Research Foundation | Full form roll finishing technique |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| PL205294B1 (pl) | 1998-09-24 | 2010-03-31 | Upjohn Co | Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| ES2235854T3 (es) | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
| US20040092511A1 (en) | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| US20070059367A1 (en) | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
| US20020115727A1 (en) | 2000-12-04 | 2002-08-22 | Senanayake Chris H. | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| US20020107244A1 (en) | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| US20040121010A1 (en) | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| JP4288263B2 (ja) | 2002-10-25 | 2009-07-01 | コレジウム ファーマシューティカル, インク. | p−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法 |
| FR2846559B1 (fr) | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| US7794403B2 (en) | 2004-04-21 | 2010-09-14 | Mear Holding B.V. | System for measuring pulsatile vascular resistance |
| JP4834837B2 (ja) | 2004-04-30 | 2011-12-14 | 国立大学法人 千葉大学 | 精神神経疾患の治療薬 |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| CN101132777A (zh) | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| EP1844000B1 (en) | 2004-12-23 | 2010-01-27 | Xenoport, Inc. | Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
| JP2008536866A (ja) | 2005-04-15 | 2008-09-11 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | アミン作動性医薬組成物および方法 |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| AU2006308889A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| CA2644458A1 (en) | 2006-03-01 | 2007-09-07 | Galderma Research & Development | Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof |
| KR101450356B1 (ko) * | 2006-11-24 | 2014-10-15 | 에이씨 이뮨 에스.에이. | 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 n-(메틸)-1h-피라졸-3-아민, n-(메틸)-피리딘-2-아민 및 n-(메틸)-티아졸-2-아민 유도체 |
| WO2008074896A1 (en) | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
| US8586627B2 (en) | 2007-05-03 | 2013-11-19 | Jack L. Arbiser | Honokiol analogs and their use in treating cancers |
| EP2219449A4 (en) | 2007-11-16 | 2010-10-27 | Univ Arizona State | METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING |
| CL2007003877A1 (es) | 2007-12-28 | 2008-06-27 | Univ De Concepcion Lab Androma | Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina. |
| ES2563061T3 (es) | 2008-04-28 | 2016-03-10 | Zogenix, Inc. | Nuevas formulaciones para el tratamiento de la migraña |
| KR101653707B1 (ko) | 2008-05-29 | 2016-09-02 | 알바니 몰레큘라 리써치, 인크. | 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도 |
| JP5514827B2 (ja) | 2008-09-25 | 2014-06-04 | バイオランド リミテッド | 4−o−メチルホノキオールを含有するアミロイド関連疾患の治療又は予防用組成物 |
| WO2010041279A2 (en) | 2008-10-08 | 2010-04-15 | V.B. Medicare Pvt. Ltd. | Sustained release drug delivery system |
| US20100099701A1 (en) | 2008-10-20 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Isoquinolinone modulators of 5-ht3 receptors |
| CN101444508B (zh) | 2008-12-29 | 2010-10-27 | 海南瑞基药物研究有限公司 | 一种注射用托烷司琼制剂及其制备方法 |
| EP2432437A4 (en) | 2009-05-21 | 2012-12-19 | Bionex Pharmaceuticals Llc | TWO- AND ONE-LAYER DOSAGE FORMS |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| US9790109B2 (en) * | 2010-04-30 | 2017-10-17 | General Electric Company | Method for sanitizing an electrodeionization device |
| ES2705027T3 (es) | 2010-08-19 | 2019-03-21 | Buck Institute For Age Res | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados |
| KR101368587B1 (ko) | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| US20150030683A1 (en) | 2012-02-18 | 2015-01-29 | Buck Institute For Research On Aging | Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions |
-
2011
- 2011-08-19 ES ES11818848T patent/ES2705027T3/es active Active
- 2011-08-19 EP EP11818848.1A patent/EP2605655B1/en active Active
- 2011-08-19 JP JP2013525003A patent/JP6250394B2/ja active Active
- 2011-08-19 DK DK11818848.1T patent/DK2605655T3/en active
- 2011-08-19 WO PCT/US2011/048472 patent/WO2012024616A1/en not_active Ceased
- 2011-08-19 CA CA2808630A patent/CA2808630A1/en not_active Abandoned
- 2011-08-19 MX MX2013001917A patent/MX353096B/es active IP Right Grant
- 2011-08-19 US US13/213,960 patent/US10449177B2/en active Active
- 2011-08-19 AU AU2011291506A patent/AU2011291506B2/en not_active Ceased
- 2011-08-19 BR BR112013003847A patent/BR112013003847A8/pt not_active IP Right Cessation
-
2016
- 2016-08-18 JP JP2016160482A patent/JP2016193944A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534256A5 (https=) | ||
| JP7398836B2 (ja) | R-ケタミンおよびその塩の医薬品としての応用 | |
| JP2017075173A5 (https=) | ||
| JP2015510941A5 (https=) | ||
| JP2018035197A5 (https=) | ||
| FI3478712T3 (fi) | Anti-N3pGlu beeta-amyloidipeptidi -vasta-aineita ja niiden käyttöjä | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2012530723A5 (https=) | ||
| JP2021525729A5 (https=) | ||
| US10342807B2 (en) | Pharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EA201400183A1 (ru) | Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства | |
| JP2011504474A5 (https=) | ||
| JP2019513814A5 (https=) | ||
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| RU2016102092A (ru) | Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений | |
| MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
| WO2020165802A1 (en) | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors | |
| WO2011058262A1 (fr) | Médicament inhalable à base de xénon pour traiter ou pour prévenir les dyskinésies induites | |
| JP2009178162A5 (https=) | ||
| CA3138389A1 (en) | Rebamipide for use in prevention and/or treatment of synucleinopathies | |
| JP2016528171A5 (https=) | ||
| JP2020527172A5 (https=) | ||
| RU2019101210A (ru) | Производное оксазина для применения в предупреждении болезни альцгеймера у пациентов, находящихся в группе риска | |
| EP3137097A1 (en) | Treatment and prevention of alzheimer's disease (ad) |